Federica Guffanti

8PUBLICATIONS
42CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 31, 2026
Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells.

|Jun 26, 2025
Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas.

Federica Guffanti, Ilaria Mengoli, Francesca Ricci

|Jul 22, 2024
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.

Michela Chiappa, Alessandra Decio, Luca Guarrera

|Mar 13, 2024
Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.

Michela Chiappa, Federica Guffanti, Chiara Grasselli

|Sep 09, 2023
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair.

Monica Ganzinelli, Federica Guffanti, Anna Ianza

|Apr 12, 2022
Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells.

Michela Chiappa, Federica Guffanti, Martina Anselmi

Pageof 2

Frequent Collaborators

5 joint publications

Giovanna Damia

4 joint publications

Michela Chiappa

2 joint publications

Massimo Broggini

2 joint publications

Francesca Ricci